FASLG

FASLG Full Name

Fas ligand (TNF superfamily, member 6)

FASLG Introduction

FAS ligand (FASLG), also known as CD95L, is a type II transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily and functions as the natural ligand for the Fas receptor (CD95). This ligand–receptor pair forms one of the most well-characterized apoptosis-inducing signaling pathways in the immune system. FASLG is primarily expressed on activated T lymphocytes, natural killer (NK) cells, and certain immune regulatory cells, where it helps eliminate virus-infected, damaged, or malignant cells. When FASLG binds to the Fas receptor on target cells, it triggers the formation of the death-inducing signaling complex and initiates the caspase cascade, ultimately leading to programmed cell death. For researchers investigating immune homeostasis or immune escape mechanisms, the FASLG-Fas pathway represents a central checkpoint that balances immune activation with controlled cell elimination.

Beyond its classical role in apoptosis, FASLG has emerged as a critical mediator in immune surveillance and anti-tumor cytotoxicity. Recent research has shown that immune cells can utilize FASLG in combination with other TNF superfamily ligands to exert potent cytotoxic effects against tumor cells. For example, activated B cells have been reported to participate in innate anti-cancer responses by engaging multiple death-inducing ligands simultaneously, with FASLG acting as a cooperative effector that enhances tumor cell killing. This finding highlights an important challenge in cancer biology: while immune cells possess intrinsic mechanisms to recognize and eliminate malignant cells, tumors often evolve strategies to resist FAS-mediated apoptosis. Understanding how FASLG contributes to immune-mediated cytotoxicity therefore provides valuable insight for researchers developing immunotherapies aimed at restoring effective tumor surveillance.

Alterations in FASLG expression or genetic variation in the FASLG gene have also been associated with disease progression in multiple cancers and immune disorders. Studies investigating copy number variations and transcriptional regulation have shown that abnormal FASLG expression can correlate with tumor aggressiveness and patient prognosis in certain malignancies, including lymphomas and invasive breast cancer. In addition, elevated FASLG expression has been explored as a potential biomarker in specific tumor types such as pancreatic neuroendocrine neoplasms, where it may help predict recurrence or disease progression. Beyond oncology, defects in the Fas–FASLG pathway are strongly linked to immune dysregulation, autoimmune disorders, and impaired lymphocyte apoptosis. These findings underscore the growing importance of FASLG as both a mechanistic research target and a potential diagnostic or therapeutic biomarker, particularly for scientists seeking to understand how immune signaling pathways influence cancer development and immune tolerance.

Alternate Names for FASLG

FASL; Fas ligand (TNF superfamily, member 6); tumor necrosis factor ligand superfamily member 6; soluble form; Apoptosis (APO 1) antigen ligand 1; Apoptosis antigen ligand; APT1LG1; APTL; CD178; CD178 antigen; CD95 ligand; CD95-L; CD95L protein; FAS antig

• 1.Janjic BM, et al.; Human B Cells Mediate Innate Anti-Cancer Cytotoxicity Through Concurrent Engagement of Multiple TNF Superfamily Ligands. Front Immunol. 2022, 13:837842.
  2.Fletcher EA, et al.; Programmatically Efficient Separation of Immune Infiltrate and Tumor Gene Expression Overlap Potentials in a Big Data Setting: FASLG Gene Expression-related Survival Distinctions. Cancer Genomics Proteomics. 2025, 22(5):716-724.